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Objectives: Stentless aortic valve replacements show improved hemodynamics due to larger orifice area and lower
transvalvular gradients in short and mid-term follow-up. Hemodynamic long-term behavior and the adaptation of
the left ventricle as well as valve-durability in patients aged ≤60 years remains unclear.
Methods: 7 to 16 years after aortic valve replacement, 54 patients (mean age at operation 53.1 ± years) received
echocardiography and clinical examination. Mean follow-up time was 10.8 ± 2.2 years. Evaluated were NYHA class,
transvalvular gradients, estimated aortic valve orifice area, degree of aortic valve insufficiency, left ventricular mass
and function.
Results: At follow-up only one patient presented with NYHA class III. All other patients were in NYHA class I or II.
Maximum and mean pressure gradients of the prostheses were 16.3 ± 7.4 mmHg and 9.1 ± 4.2 mmHg, respectively.
Compared to echocardiography at discharge the mean pressure gradients dropped 18.0% (2.0 ± 0.9 mmHg) and stayed
stable until 14 years after the operation. Only 5 patients showed relevant regurgitation (at 13–16 years after valve
replacement), 49 showed no or trivial regurgitation. Left ventricular mass had decreased 26.5% (107.9 ± 18.5 g).
Left ventricular ejection fraction (LVEF) had increased in most patients and decreased in only one. For patients
with preoperatively impaired left ventricular function an increase of LVEF of 13.1 ± 3.1% was seen.
Conclusion: Porcine stentless aortic valves provide excellent hemodynamic long-term results without significant rise of
transvalvular pressure gradients or relevant insufficiencies until 14 years after implantation, leading to sustained decrease
of left ventricular mass and improvement of left ventricular function.Background
Stentless aortic valve replacements (SAVR) were de-
signed by avoiding an obstructive stent [1]. Due to this
difference, SAVR show a larger orifice area, lower
transvalvular gradients and improved hemodynamics
compared to stented aortic valve replacement [2]. The
occurrence of a patient-prosthesis-mismatch could be
ruled out with SAVR [3]. These advantages led in com-
parison to stented bioprostheses to reduced left ven-
tricular mass and improved survival in short and
midterm follow-up [4]. It may also lead to improved
survival and left ventricular function in long-term
follow-up. The main disadvantage of bioprostheses is
their limited durability, especially in younger patients.
Therefore the American Heart Association and the
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above the age of 60 years, for patients under the age of
60 years the use of mechanical aortic valve replace-
ments is recommended [5]. Nonetheless, in long term
follow-up survival between mechanical and stented bio-
prostheses slightly favored the latter [6], despite the
higher risk of reoperation. The superior hemodynamic
properties of SAVR may lead to a higher durability
compared to stented bioprostheses. We already re-
ported intermediate to long term results of SAVR in pa-
tients under 60 years [7,8]. Yet no long-term follow-up
of the hemodynamic performance of SAVR with its im-
plication on durability in younger patients has been
published.Methods
The study was approved by the Ethikausschuss institu-
tional review board on the local Ethics Committee.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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SAVR in our center 7 to 16 years ago and were 60 years
old or younger at the time of operation. Of the identified
64 patients with the originally implanted valve still in
place 54 patients gave informed consent to the clinical
trial and received clinical examination and echocardiog-
raphy. Mean age of the patients at operation was 53.1 ±
7.7 years. Mean follow-up time was 10.8 ± 2.2 years.
Captured and analyzed were NYHA class, maximum
and mean transvalvular pressure gradient, effective aortic
valve orifice area (EOA), degree of aortic valve insuffi-
ciency, left ventricular mass and left ventricular function.
Standard techniques were used to obtain echocardio-
graphic measurements, in accordance with the guide-
lines of the German Society of Ultrasound in Medicine
[9]. Pulsed wave Doppler was used to measure mean and
maximum systolic blood flow velocities in the left ven-
tricular outflow tract, and continuous wave Doppler was
used to measure systolic blood flow velocities across the
aortic valve. Peak and mean transvalvular gradients were
obtained using the modified Bernoulli equation. TheFigure 1 Long-term survival of the study population in Kaplan-MeierEOA and left ventricular mass were calculated with the
continuity equation [10] and the ASE equation [11],
respectively.
Statistical analysis
All data were analyzed with IBM SPSS Statistics version
21 (IBM Corporation). Descriptive statistics are reported
as the mean ± standard deviation for continuous vari-
ables and as frequencies and percentages for categorical
variables, unless otherwise noted. Normal distribution
was tested by the Shapiro-Wilk-test. Normally distrib-
uted data were analyzed using the Students t-test, while
the Wilcoxon test was used for non-normally distributed
data. All p values were two-sided. Statistical significance
was set at a p value of less than 0.05.
Results
Five different porcine SAVR were implanted in the study
population. Implanted valves were: 36 Edwards Prima
Plus, 12 St. Jude Medical Toronto SPV™, 3 Vascutek
Elan™, 2 Medtronic Freestyle® and 1 Shelhigh stentlessanalysis.
Figure 3 Pressure gradient and effective orifice area depending
on labelled size of valve.
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25 mm and 29 mm in diameter. Mean valve size was
27.4 ± 1.3 mm.
At follow-up only one patient presented with NYHA
class III. All other patients were in NYHA class I or II.
Survival analysis of the whole study population is pre-
sented in Figure 1. At 5 and 10 years a long-term sur-
vival of 91.5 ± 2.2% and 76.7 ± 3.4%, respectively, was
observed.
Maximum and mean pressure gradients were 16.3 ±
7.4 mmHg and 9.1 ± 4.2 mmHg, respectively. The mean
pressure gradients of the prostheses at time of follow-up
decreased 20.8% compared to pressure gradients directly
after implantation of SAVR. Figure 2 shows maximum
and mean pressure gradients depending on duration of
implantation. No relevant difference could be found be-
tween the different intervals of implantation until
14 years after implantation. Afterwards one can see a
rise in transvalvular gradients. Different sizes of the im-
planted SAVR did not lead to relevant differences be-
tween pressure gradients, but different EOAs could be
observed (Figure 3).
Left ventricular mass was captured in all except 9 pa-
tients prior to the aortic valve replacement and in all pa-
tients at follow-up. Considering this, a reduction of left
ventricular mass in 84% of the patients was achieved
(Figure 4). Analysis of all examined patients showed a
reduction in left ventricular mass of 26.5% (p < 0.01). For
patients with preoperative hypertrophy of more than
170 g/m2 a reduction of 30% could be observed (p <
0.01). Between the different time intervals (7–16 years)
after operation no significant differences were found,
pointing to an already completed left ventricular remod-
eling 7 years after the operation.
Left ventricular function increased in 17 patients and
decreased in one patient while in remaining patients it
persisted (Figure 5). For the whole cohort an increase of
left ventricular ejection fraction of 3.67 ± 1.7% could beFigure 2 Pressure gradient and effective orifice area depending
on the year after implantation.seen (p = 0.03), for the patients with preoperative im-
paired left ventricular function an increase of 13.0 ± 3.0%
could be observed (p < 0.01).
One patient showed a severe regurgitation. The pros-
thesis was implanted 15 years ago and 3 months after
the follow-up a successful reoperation was performed.
Additionally, we found 4 cases with moderate insuffi-
ciencies. These patients received the SAVR 13–14 years
ago and showed no clinical symptoms of the aortic in-
sufficiency. The remaining 49 patients showed no or
trivial insufficiencies.
Freedom from reoperation at 5 and 10 years was
96.2 ± 1.5% and 81.0% ± 3.4%, respectively (Figure 6).
Discussion
Stentless aortic valves promised excellent hemodynamic
behavior mediated by a larger orifice area and a more
physiological flow pattern. Short-term and mid-term
follow-up, recapitulated in a meta-analysis by Kunadian
[2], confirmed this excellent hemodynamic behavior in
comparison to stented bioprostheses. The author showed
that the use of a SAVR resulted in a larger effective orifice
area and lower transvalvular gradients compared to
stented valves. Our long term results showed constantly
low transvalvular gradients up to 14 years after implant-
ation. EOAs were calculated 1.6, 1.8 and 2.1 cm2 for 25,
27 and 29 mm valve sizes, respectively. However, captured
pressure gradients were lower than for most stented
bioprostheses, regardless of intraannular or supraannu-
lar implantation. For example, the Edwards Lifesciences
Perimount Magna™ and Medtronic Hancock II® showed
for the labeled sizes 25 mm, 27 mm, 29 mm EOAs of
1.4 cm2, 1.5 cm2, 1.8 cm2 and 1.3 cm2, 1.4 cm2,
1.8 cm2, respectively [12]. For the stented bioprosthesis
St. Jude Medical Trifecta™ lower pressure gradients or
higher EOA’s for the 3 different valve sizes have been
reported [13]. This newer bioprosthesis, however, still
has to stand the test of time.
Figure 4 Development of left ventricular mass in each patient (lines) and for the whole echocardiographicly examined study cohort
(Boxplots: box equals interquartile range with median and whiskers of 1.5× interquartile range).
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regression of left ventricular mass and left ventricular re-
modeling. Left ventricular hypertrophy develops in pa-
tients with aortic stenosis as an adaptation to increased
pressure load. Incomplete regression of left ventricular
hypertrophy after aortic valve replacement is associatedFigure 5 Development of left ventricular function.with an increased mortality [14]. The observed regression
of left ventricular hypertrophy in our study is a conse-
quence of the hemodynamic properties of the SAVR. The
remodeling process is also leading to an improvement of
left ventricular function, which was observed in our study.
Additionally, no relevant insufficiency could be shown till
14 years after operation. This lack of volume overload also
supports the left ventricular remodeling.
The limited durability of biological valves and con-
secutive reoperations are the major concern for the use
of bioprostheses in younger patients. Therefore current
guidelines recommend the use of mechanical AVR in pa-
tients under 60 years [5]. The superior hemodynamic
performance of SAVR could lead to a better durability
due to less stress on the cusps of the SAVR. The previ-
ously published freedom from reoperation with a median
of 14.43 ± 0.54 years in our cohort [7] supports this hy-
pothesis. Literature research showed that most other
biological aortic valves in younger patients tend to fail
earlier [7,8]. Our data showed an at least similar durabil-
ity of SAVR compared to stented bioprostheses in youn-
ger patients for the first 14 years [7]. However, durability
is inferior to mechanical valves. The risk of reoperation
in case of bioprostheses must be weighed against the
risk of thromboembolic or bleeding events with a mech-
anical valve [15]. Ruel et al. [6] showed that these differ-
ent risks regarding valve replacements led to slightly
superior survival in patients with bioprostheses during
25 years follow-up.
Aortic valve repair with various valve sparing tech-
niques is an alternative to valve replacement and often
Figure 6 Freedom from reoperation of the study population in Kaplan-Meier analysis.
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useful option in carefully selected patients, mostly with
isolated aortic valve regurgitation. Minakata et al. [16]
published reoperation rates of 11% and 15% at 5 and
7 years, respectively. A systematic review by Carr et al.
[17] reported 5 and 10 year freedom from reoperation of
89% and 64%. These data led to concerns about long
term durability after aortic valve repair and are inferior
to the presented results with stentless bioprostheses.
The impact of the hemodynamic performance of SAVR
on patient-survival has been shown in midterm follow-up
[4]. Figure 1 shows the long-term survival of our study
population. Detailed characteristics of this study cohort
were previously published [7]. For patients with isolated
aortic valve stenosis and normal left ventricular function
survival was comparable to the general population [7].
Additionally, comparison with the literature showed that
mortality in our study population was comparable to
mechanical or stented biological aortic valves [7,8]. Thus,
SAVR led to the same survival during long-term follow-up
with better hemodynamic properties.Limitations
A limitation is the small study population, especially at
15 and 16 years after the operation. The implantation of
SAVR in patients aged 60 years or younger, however,
was not the standard procedure and no other long-term
follow-up for such a cohort is available. Cardiac sono-
graphers and echocardiography systems have changed
over the 16 years of follow-up, which may lead to a bias
of data.Conclusion
SAVR in patients aged 60 years or younger provides excel-
lent hemodynamic long-term results without significant
rise of transvalvular pressure gradients or profound regur-
gitation until 14 years after the operation. Consequently,
reoperation rates remained low. The hemodynamic per-
formance led to left ventricular mass regression and im-
provement of left ventricular function in the study
population, particularly in patients with advanced myocar-
dial hypertrophy or poor left ventricular function. Thus,
Christ et al. Journal of Cardiothoracic Surgery  (2014) 9:197 Page 6 of 6SAVR is an alternative to mechanical valves or valve spar-
ing techniques in younger patients.
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